Skip to main content

Table 1 Baseline patient demographics and disease characteristics

From: Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

  ITT population Biomarker population
Adalimumab 40 mg q2w (n = 185) Sarilumab 200 mg q2w (n = 184) Adalimumab 40 mg q2w (n = 154) Sarilumab 200 mg q2w (n = 153)
Age, years 53.6 (11.9) 50.9 (12.6) 53.3 (12.0) 50.4 (12.5)
Sex, female, % 81.1 85.3 78.6 83.7
Duration of RA, years 6.6 (7.8) 8.1 (8.1) 6.6 (8.1) 7.9 (8.1)
ACPA positive, % 76.7 75.3 76.2 73.8
RF positive, % 64.8 66.9 63.8 66.0
Treated with 1/2/≥ 3 prior csDMARDs/immunosuppressive agents, % 47.6/31.4/21.1 45.1/31.0/23.9 48.1/31.8/20.1 46.4/32.0/21.6
Oral corticosteroid use, % 56.2 53.3 57.1 51.6
Tender joint count 26.7 (13.6) 28.0 (13.2) 26.9 (13.9) 28.1 (13.4)
Swollen joint count 17.5 (10.3) 18.6 (10.7) 17.3 (10.1) 18.5 (10.6)
HAQ-DI 1.6 (0.6) 1.6 (0.6) 1.6 (0.6) 1.6 (0.6)
CRP, mg/L 24.1 (31.0) 17.4 (21.3) 23.6 (31.1) 17.4 (21.9)
DAS28-ESR 6.8 (0.8) 6.8 (0.8) 6.8 (0.8) 6.8 (0.8)
DAS28-CRP 6.0 (0.9) 6.0 (0.9) 6.0 (0.9) 6.0 (0.9)
CDAI 42.4 (12.0) 43.6 (12.1) 42.8 (11.9) 43.8 (12.0)
Pain VAS (0–100 mm) 71.4 (19.0) 71.6 (18.7) 71.3 (18.6) 71.2 (19.1)
Patient global VAS (0–100 mm) 67.8 (18.4) 68.0 (17.5) 68.6 (18.2) 67.8 (17.9)
SF-36 PCS 31.4 (6.6) 30.7 (6.2) 31.5 (6.5) 30.4 (6.2)
SF-36 MCS 37.1 (11.8) 36.7 (10.7) 37.4 (12.4) 37.0 (11.2)
Morning stiffness VAS (0–100 mm) 68.0 (21.4) 70.8 (19.0) 68.2 (21.7) 70.6 (18.8)
FACIT-fatigue (0–52) 24.0 (10.3) 24.0 (9.0) 23.9 (10.4) 23.4 (9.1)
Physician global VAS (0–100 mm) 66.0 (17.1) 66.3 (15.7) 66.2 (16.4) 67.3 (14.9)
RAID (0–10) 6.4 (2.0) 6.7 (1.7) 6.4 (2.1) 6.6 (1.7)
  1. Mean (standard deviation) unless otherwise stated
  2. ACPA anti-citrullinated protein antibody, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, DAS28-CRP Disease Activity Score (28 joints) using C-reactive protein, DAS28-ESR Disease Activity Score (28 joints) using erythrocyte sedimentation rate, FACIT Functional Assessment of Chronic Illness Therapy, HAQ-DI Health Assessment Questionnaire-Disability Index, ITT intent-to-treat, MCS mental component summary, PCS physical component summary, q2w every 2 weeks, RA rheumatoid arthritis, RAID rheumatoid arthritis impact of disease, RF rheumatoid factor, SF-36 Medical Outcomes Study Short-Form (36-item) Health Survey, VAS visual analogue scale